Acute Coronary Syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordis

Acute Coronary Syndrome therapies, such as LODOCO (colchicine), TNKase (tenecteplase), REPATHA (evolocumab), ZONTIVITY (vorapaxar), PRALUENT (alirocumab), LOVENOX (enoxaparin sodium), Aggrastat (tirofiban), REOPRO (abciximab), and others, are expected to boost the Acute Coronary Syndrome Market in the upcoming years.

DelveInsight has launched a new report on "Acute Coronary Syndrome - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Acute Coronary Syndrome, historical and forecasted epidemiology as well as the Acute Coronary Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Acute Coronary Syndrome market report @ https://www.delveinsight.com/report-store/acute-coronary-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Acute Coronary Syndrome Market Report:

In 2023, the Acute Coronary Syndrome (ACS) market across the seven major markets (7MM) was valued at approximately USD 2,670 million, with projections indicating a substantial compound annual growth rate (CAGR) throughout the forecast period (2020-2034). The United States held the largest share, representing about 80% of the total ACS market in 2023.
As of April 2024, results from the EMPACT-MI trial indicated that JARDIANCE (empagliflozin) did not show a statistically significant reduction in the combined risk of all-cause mortality and heart failure-related hospitalizations in patients with acute myocardial infarction (AMI) who were at elevated risk of developing heart failure, compared to a placebo.
In February 2024, CSL released top-line findings from its Phase III AEGIS-II trial assessing the safety and effectiveness of CSL112 (apolipoprotein A-I [human]) in reducing major adverse cardiovascular events (MACE) in post-AMI patients. The trial did not achieve its primary efficacy endpoint of reducing MACE within 90 days. Consequently, the company has no immediate plans for a regulatory submission. However, CSL112 was generally well tolerated, with no major safety concerns reported.
A September 2023 update from DalCor Pharmaceuticals stated that an interim efficacy analysis of the Dal-GenE-2 trial is expected in 2026, with full trial completion targeted for 2027. In the same month, the company announced it had secured USD 80 million in Series D funding to support the Dal-GenE-2 confirmatory trial in North America, conducted under a Special Protocol Assessment (SPA) agreement with the U.S. FDA.
The overall incidence of ACS in the 7MM was estimated at around 2,195,300 cases in 2023, with the highest number of new cases reported in the United States. Within the U.S., Non-ST-Elevation Myocardial Infarction (NSTEMI) cases were more prevalent than ST-Elevation Myocardial Infarction (STEMI), accounting for approximately 607,300 cases that year.
In 2023, the number of Acute Coronary Syndrome cases in males across the EU4 countries and the UK was approximately 514,410, while females accounted for around 269,750 cases.
In Japan, there were an estimated 45,700 cases of ST-Elevation Myocardial Infarction (STEMI) and about 34,500 cases of Non-ST Elevation Myocardial Infarction (NSTEMI) reported during the same year.
The recent FDA approval of LODOCO by AGEPHA Pharma marks a milestone in ACS treatment. For the first time, patients with residual inflammatory risk have access to an approved therapy specifically aimed at reducing cardiovascular disease risk. LODOCO functions by targeting the inflammatory pathways involved in major cardiac events.
Key Acute Coronary Syndrome companies such as Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra, and others are evaluating new drugs for Acute Coronary Syndrome to improve the treatment landscape.
Promising Acute Coronary Syndrome therapies include LODOCO (colchicine), TNKase (tenecteplase), REPATHA (evolocumab), ZONTIVITY (vorapaxar), PRALUENT (alirocumab), LOVENOX (enoxaparin sodium), Aggrastat (tirofiban), REOPRO (abciximab), and others.

Acute Coronary Syndrome Overview

Acute Coronary Syndrome (ACS) refers to a group of conditions characterized by a sudden or severe reduction in blood flow to the heart muscle, which can lead to damage. Conditions under the ACS umbrella include heart attacks and unstable angina, as well as ST-Elevation Myocardial Infarction (STEMI) and Non-ST Elevation Myocardial Infarction (NSTEMI). ACS is a form of Coronary Heart Disease (CHD), a leading cause of mortality, accounting for one-third of all deaths in individuals over the age of 35. While some types of CHD may not present symptoms, ACS always manifests with noticeable clinical signs.

Typically, the blockage that causes ACS results from a blood clot, often triggered by the rupture of a plaque within a coronary artery. Part of the clot may dislodge and obstruct blood flow, leading to ACS. In rarer cases, coronary artery spasms can also restrict blood flow. Regardless of the underlying cause, such blockages are harmful to the heart and constitute a medical emergency.

Acute Coronary Syndrome Market Outlook

The treatment approach for Acute Coronary Syndrome (ACS) aims to alleviate symptoms, prevent blood clot formation, restore blood flow to the heart, minimize the extent of heart muscle damage, reduce the heart's workload, and manage or prevent potential complications. Management strategies typically involve revascularization procedures-such as percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or fibrinolytic therapy-along with medication to address both ACS and the underlying coronary artery disease.

Discover how the Acute Coronary Syndrome market is rising in the coming years @ https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Coronary Syndrome Marketed Drugs
LODOCO (colchicine): AGEPHA Pharma
REPATHA (evolocumab): Amgen

Acute Coronary Syndrome Emerging Drugs
Dalcetrapib (RO4607381): DalCor Pharmaceuticals and Roche
Dutogliptin: Recardio

Scope of the Acute Coronary Syndrome Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute Coronary Syndrome Companies: Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra, and others
Key Acute Coronary Syndrome Therapies: LODOCO (colchicine), TNKase (tenecteplase), REPATHA (evolocumab), ZONTIVITY (vorapaxar), PRALUENT (alirocumab), LOVENOX (enoxaparin sodium), Aggrastat (tirofiban), REOPRO (abciximab), and others
Acute Coronary Syndrome Therapeutic Assessment: Acute Coronary Syndrome current marketed and Acute Coronary Syndrome emerging therapies
Acute Coronary Syndrome Market Dynamics: Acute Coronary Syndrome market drivers and Acute Coronary Syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Acute Coronary Syndrome Unmet Needs, KOL's views, Analyst's views, Acute Coronary Syndrome Market Access and Reimbursement

To know what's more in our Acute Coronary Syndrome report, visit https://www.delveinsight.com/report-store/acute-coronary-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Acute Coronary Syndrome Market Report:
Acute Coronary Syndrome market report covers a descriptive overview and comprehensive insight of the Acute Coronary Syndrome Epidemiology and Acute Coronary Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Acute Coronary Syndrome market report provides insights into the current and emerging therapies.
The Acute Coronary Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Acute Coronary Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Coronary Syndrome market.

Got queries? Click here to know more about the Acute Coronary Syndrome market Landscape https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Acute Coronary Syndrome Patient Share (%) Overview at a Glance
5. Acute Coronary Syndrome Market Overview at a Glance
6. Acute Coronary Syndrome Disease Background and Overview
7. Acute Coronary Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Coronary Syndrome
9. Acute Coronary Syndrome Current Treatment and Medical Practices
10. Unmet Needs
11. Acute Coronary Syndrome Emerging Therapies
12. Acute Coronary Syndrome Market Outlook
13. Country-Wise Acute Coronary Syndrome Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Acute Coronary Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Acute Coronary Syndrome Market Outlook 2034 https://www.delveinsight.com/report-store/acute-coronary-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Acute Coronary Syndrome Pipeline Insights, DelveInsight

"Acute Coronary Syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute Coronary Syndrome market. A detailed picture of the Acute Coronary Syndrome pipeline landscape is provided, which includes the disease overview and Acute Coronary Syndrome treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.